Psoriasis is a chronic autoimmune condition that primarily affects the skin, causing red, scaly patches. It is estimated that around 2-3% of the global population, or over 125 million people, suffer from some form of psoriasis. The condition ranges from mild to severe, with moderate psoriasis being particularly prevalent. Current treatments, such as topical corticosteroids, biologics, and phototherapy, often fail to provide long-lasting relief, creating a high unmet clinical need for better therapies. As targeted therapies and precision medicine gain more focus, the development of innovative drugs, especially biologics, is expected to drive significant growth in the moderate psoriasis pipeline in the coming years, offering hope for more effective treatments.
The Moderate Psoriasis Drug Pipeline Insight Report by Expert Market Research gives comprehensive insights into moderate psoriasis therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for moderate psoriasis. The moderate psoriasis report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The moderate psoriasis pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with moderate psoriasis treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to moderate psoriasis.
Moderate psoriasis is a chronic autoimmune skin disorder characterized by inflamed, red, and scaly plaques covering 3-10% of the body. It occurs when an overactive immune system accelerates skin cell turnover, leading to excessive buildup. Genetic predisposition, environmental triggers, and immune dysfunction contribute to its development. Stress, infections, and certain medications can worsen symptoms, impacting patients' quality of life.
Moderate psoriasis treatment includes topical therapies like corticosteroids and vitamin D analogs, phototherapy, and systemic treatments. Biologic drugs targeting immune pathways, such as IL-17 and IL-23 inhibitors, offer advanced options. Traditional systemic therapies like methotrexate and cyclosporine are also prescribed. Personalized treatment plans, integrating lifestyle modifications and emerging therapies, continue to improve patient outcomes.
Psoriasis affects 2-3% of the global population, with over 125 million cases worldwide. In the United States, its prevalence is 1.4%, while the United Kingdom has prevalence rates between 0.7% and 2.6%. Japan has over 500,000 cases at a 0.34% prevalence, which is expected to rise. In India, prevalence ranges from 0.44% to 2.8%. Advancements in biologics and targeted therapies are driving drug pipeline growth.
This section of the report covers the analysis of moderate psoriasis drug candidates based on several segmentations, including:
By Phase
By Drug Class
By Route of Administration
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase III covers a major share of the total moderate psoriasis clinical trials.
The drug molecule categories covered under the moderate psoriasis pipeline analysis include small molecules, monoclonal antibodies, gene therapies, and topical therapies. The phase III report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for phase III.
The EMR report for the moderate psoriasis drug pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed moderate psoriasis therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in moderate psoriasis clinical trials:
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for moderate psoriasis. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of moderate psoriasis drug candidates.
A Phase IV study sponsored by Suzhou Suncadia Biopharmaceuticals Co., Ltd. aims to evaluate the efficacy and safety of Vunakizumab in adults with moderate-to-severe plaque psoriasis who have transitioned from other biologics. The study will also assess patient satisfaction and reported outcomes. The study is expected to enroll nearly 1,564 participants and is projected to be completed by February 2028.
Janssen Research & Development is sponsoring a Phase IIIb study, that evaluates the efficacy of Guselkumab versus placebo in treating low body surface area moderate plaque psoriasis with special site involvement. The study aims to assess safety and effectiveness. It is expected to conclude by April 2025, with approximately 338 participants estimated to enroll.
The Phase II study, sponsored by UCB Biopharma SRL, evaluates the pharmacokinetics, safety, and efficacy of two doses of Bimekizumab in adolescents with moderate to severe plaque psoriasis. The study will involve about 41 participants and aims to assess subcutaneous administration. It is expected to be completed by March 2025.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The Moderate Psoriasis Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for moderate psoriasis. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into moderate psoriasis collaborations, regulatory environments, and potential growth opportunities.
Global Psoriasis Treatment Market
Psoriasis Epidemiology Forecast
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
United States
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
Share